000 01059 a2200253 4500
005 20250518032034.0
264 0 _c20200601
008 202006s 0 0 eng d
022 _a1873-7560
024 7 _a10.1016/j.eururo.2019.03.013
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLeibowitz-Amit, Raya
245 0 0 _aReply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53.
_h[electronic resource]
260 _bEuropean urology
_c07 2019
300 _ae19 p.
_bdigital
500 _aPublication Type: Letter; Comment
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aProstatic Neoplasms
650 0 4 _aProstatic Neoplasms, Castration-Resistant
650 0 4 _aRadium
773 0 _tEuropean urology
_gvol. 76
_gno. 1
_gp. e19
856 4 0 _uhttps://doi.org/10.1016/j.eururo.2019.03.013
_zAvailable from publisher's website
999 _c29533047
_d29533047